{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038894","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.055727+00:00","generated_at":"2026-06-04T04:38:23.787820+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Axsome initiates Phase 3 ENGAGE trial of solriamfetol for binge eating disorder","bullets":["Initiated ENGAGE Phase 3 trial of solriamfetol for binge eating disorder.","Trial is randomized, double-blind, placebo-controlled with ~450 patients.","Two doses (150 mg and 300 mg) vs placebo for 12 weeks; primary endpoint is change in binge eating episodes.","First patient screened in March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038894","json":"https://secwatch.observer/filing/0000950170-24-038894.json","markdown":"https://secwatch.observer/filing/0000950170-24-038894.md","text":"https://secwatch.observer/filing/0000950170-24-038894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024038894/0000950170-24-038894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024038894/axsm-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:38:23.787820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}